Targeted delivery of cancer drug paclitaxel to chordomas tumor cells via an RNA nanoparticle harboring an EGFR aptamer

This publication has 55 references indexed in Scilit:

• Fabrication of pRNA nanoparticles to deliver therapeutic RNAs and bioactive compounds into tumor cells
  Nature Protocols, 2013
• Current therapeutic options and novel molecular markers in skull base chordomas
  Neurosurgical Review, 2011
• Thermodynamically stable RNA three-way junction for constructing multifunctional nanoparticles for delivery of therapeutics
  Nature Nanotechnology, 2011
• A Neutralizing RNA Aptamer against EGFR Causes Selective Apoptotic Cell Death
  PLOS ONE, 2011
• PET response and tumor stabilization under erlotinib and bevacizumab treatment of an intracranial lesion non-invasively diagnosed as likely chordoma
  Clinical Neuropathology, 2011
• Frequent activation of EGFR in advanced chordomas
  Clinical Sarcoma Research, 2011
• Pharmacological Characterization of Chemically Synthesized Monomeric phi29 pRNA Nanoparticles for Systemic Delivery
  Molecular Therapy, 2011
• Rapidly Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in NSCLC Cell Lines through De-Repression of FGFR2 and FGFR3 Expression
  PLOS ONE, 2010
• Analysis of receptor tyrosine kinases (RTKs) and downstream pathways in chordomas
  Neuro-Oncology, 2010
• Target-driven exploratory study of imatinib mesylate in children with solid malignancies by the Innovative Therapies for Children with Cancer (ITCC) European Consortium
  European Journal of Cancer, 2009